![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » OSCIENT PHARMACEUTICALS CORPORATION COMPLETES ACQUISITION OF CARDIOVASCULAR THERAPY ANTARA 130MG (FENOFIBRATE) CAPSULES
OSCIENT PHARMACEUTICALS CORPORATION COMPLETES ACQUISITION OF CARDIOVASCULAR THERAPY ANTARA 130MG (FENOFIBRATE) CAPSULES
Oscient Pharmaceuticals has completed its acquisition of the U.S. rights to
the cardiovascular product ANTARA 130 mg (fenofibrate) capsules from Reliant
Pharmaceuticals. ANTARA is part of the $22 billion U.S. market for treating
dyslipidemias, which includes the $1 billion fenofibrate market. ANTARA will
be commercialized by Oscient's national sales force beginning later this week.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct